From the sample of 280 patients with mild to moderate UC parallel groups were formed. For 8 weeks, one group received 1.2 g of MMX mesalazine twice a day n = 93, another group received 4.8 g/day in a single dose n = 94, and the control group received placebos n = 93.
En el primero 22, controlado con placebo y de grupos paralelos, se incluyeron 280 pacientes con CU leve-moderada tratados con mesalazina-MMX 2,4 g/día administrados bien 1,2 g dos veces al día n=93 o 4,8 g/día en una dosis única n=94, o bien con placebo n=93, durante 8 semanas.